Novo Nordisk just got a reality check. The company's latest trial for a higher-dose Wegovy showed it helps patients shed more ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Besides diabetes, obesity is a major risk factor for hypertension and heart disease, creating what can only be described as a ...

Denmark’s Novo Nordisk saw its shares rise as much as 13% to 659.20 kroner this morning, after it announced top-line results ...

GPS systems around the world are adjusting to a new model tracking Earth's magnetic north pole, the point that attracts the ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Research has found that GLP-1 receptors, found in medications like Wegovy and Monjaro, may offer health benefits beyond the ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?